Comment on a PREreview of "Viral SSB-bound ssDNA activates the bacterial anti-phage defense system DARNA"
Year: 2026
Type: article
Abstract: This Zenodo record is a permanently preserved version of a comment on a PREreview. You can view the complete PREreview and comments at https://prereview.org/reviews/24149709. REVIEW REPORT The authors present a very intriguing anti-phage defense system named DARNA (ssDNA-Activated RNase), which provides abortive defense against diverse phages via cleaving cellular tRNAs at the anti-codon loop. The authors follow up on a previously published screen which identified the defense profile of this system. The mechanism of defense mediated by DARNA is uncovered through forward genetics, RNA sequencing, biochemical, and structural studies. Curiously, DARNA is activated by various structurally distinct phage single-stranded DNA-binding proteins (SSBs) in combination with ssDNA in vitro. The data supports the claim that in vitro SSBs are necessary, but not sufficient for DARNA activation. Since they have differing biophysical properties, structural insights into the mechanism of SSB activation would clarify how divergent proteins could lead to the same phenotype. Additionally, further data would help to understand how an inter-hexameric interface-disrupted mutant (F6A+N33A+E347A) still confers defense. Lastly, a key component of the in vitro reconstitution is a short synthetic ssDNA oligonucleotide named "34 nt." While this acts as a potent activator of DARNA in vitro, it is not representative of its likely endogenous ssDNA activating sequence during phage infection. While in vitro and structural data demonstrate that DARNA binds ssDNA, there is limited evidence showing that this occurs during infection. All in all, this preprint contains compelling data, demonstrating a new mode of molecular pattern sensing during phage infection which confers broad defense. Response. We thank the reviewers for evaluating our preprint. We wish to note that the statement "The data supports the claim that in vitro SSBs are necessary, but not sufficient for DARNA activation." is not accurate, as in our work we show that ssDNA is both necessary and sufficient for activation of DARNA in vitro. Phage SSBs is not necessary for activation in vitro, though it leads to an enhancement of the RNase activity (Figure 3A). Major Points In Supplementary Figure S4, the authors demonstrate by mass photometry that structure-guided mutations (F6A+N33A+E347A) disrupt the DARNA dodecamer. However, it appears that the mutant can still provide moderate protection against phages T4 and T5, even though in vitro its RNase activity is gone. Therefore, the phage spot assay data contradicts the suggested model that the dodecamer is required for activity and thus phage defense. It is possible that while the dodecamer is the functional unit in vitro, DARNA might behave differently during infection. It would be interesting to know if this mutant induces toxicity when co-expressed with the different phage SSBs. This would greatly improve the understanding of the system and show that while a dodecamer can bind a synthetic ssDNA oligonucleotide in vitro, a dimer is still sufficient to provide defense and be activated by SSB in vivo. Response. The apparent discrepancy between the mass photometry and in vitro activity data (no detectable dodecameric species and no RNase activity for the F6A+N33A+E347A interface mutant) and the in vivo results (partial protection against T4 and T5 phages in E. coli cells by the mutant) likely arises from differences in DARNA protein concentrations. Note that at 100 nM (in terms of monomer, concentration used in mass photometry experiments) even WT DARNA exists as an equilibrium mixture of monomeric, dimeric and dodecameric species, the latter comprising a minor fraction.The interface mutations shift this equilibrium towards monomers and dimers (Figure 3B). We therefore presume that intracellular DARNA concentrations under the phage plaque assay conditions are sufficient to allow the formation of a fraction of higher-order oligomers of the interface mutant that can support partial antiviral defense. This residual antiviral activity of the interface mutant does not undermine our conclusion that an intact oligomerization interface is essential for DARNA RNase activity, as demonstrated by the well-controlled in vitro assays. Through in vitro reactions, the authors show that a synthetic ssDNA oligonucleotide 34 bases in length is sufficient to activate DARNA-mediated tRNA cleavage. However, it is not shown how the authors arrived at this specific oligonucleotide sequence especially since there are no identical sequences present in the genome of the bacteria they studied. The DARNA system functions in vivo and therefore must have a ssDNA-binder within the cell during infection, which could be of bacterial or phage origin. Additional experiments, such as immunoprecipitation of DARNA from phage-infected cells followed by NGS of co-precipitated DNA, could potentially yield information on the endogenous ssDNA binding sequence. This information could not only provide a potentially more efficient activator but also show whether DARNA is activated by the same sequence during T3, T4, T5, and T7 phage infections. Response. As described in the preprint, we tested a series of single-stranded oligonucleotides, oligoduplexes, and oligonucleotides combining ssDNA and dsDNA segments, all based on artificially designed related sequences of different lengths. We found that the 34-nt ssDNA fragment ("34 nt") supported high levels of RNase activity, whereas its complementary sequence ("34 nt-compl") was a poor activator (Figure 3). Subsequent analysis led to the identification of a short and highly abundant "CT" sequence motif as the DARNA-binding determinant. This motif is present in three copies in the activating "34 nt" oligonucleotide, but only once in the poorly activating "34 nt-compl" oligonucleotide. The sequence-specific recognition of the CT motif by DARNA was subsequently confirmed by structural analysis of the DARNA-ssDNA complex (Figure 4E). We have not performed any further optimization of the DNA sequence. Such optimizations might involve a further increase in the number/frequency of the "CT" motifs. According to our model for DARNA-mediated antiphage defense (Figure 5C), its activation in bacterial cells requires binding to ssDNA presented by phage SSB. Though sequencing of DNA co-precipitated with DARNA and phage SSB might reveal the sequences that are naturally bound by DARNA during infection, given the sequence-independent nature of SSB interaction with ssDNA, such co-precipitated DNA would likely lack any specific sequences, except for the very short and abundant "CT" motif identified in the in vitro studies. In Figure 1C, the authors show that co-expression with phage SSBs alone induces DARNA-mediated toxicity. While the phage SSBs alone are not toxic to the bacteria, it is not clear if DARNA alone is toxic. This is especially important since later figures show that DARNA can cleave tRNA in the absence of phage SSB activators. This panel would benefit from a control with DARNA expression alone to support the claim that phage SSB activation is responsible for the toxicity. It is known that many bacterial immune systems, when overexpressed, have a growth effect. Therefore, this experiment would be strengthened by showing that DARNA has no background toxicity and the observed toxicity is solely through co-expression with SSBs. Response. An updated figure for this experiment was included in the final published version of this article (https://doi.org/10.1038/s41467-026-78638-y Figure 1). We included an additional control in which DARNA was co-expressed with an MBP control. DARNA toxicity was not observed in the absence of phage SSB proteins. Minor Points Figure 1: The main takeaway from Figure 1 is that the DARNA defense system is activated by structurally diverse phage SSBs. However, how these phage SSBs differ is not shown. Moving the structures and alignments from Figure S1B to Figure 1 would significantly aid in understanding the main claim. Response. Indeed, the structural similarities and differences between the various SSB proteins could be illustrated in the main text figure. However, we would like to point out that, in the context of DARNA activation, the most relevant differences between phage and E. coli SSBs concern their interactions with ssDNA. These interactions are resolved only in the experimental structure of E. coli SSB, whereas the available experimental structures of the phage SSBs tested do not provide this information, and their ssDNA-bound structures cannot be reliably modeled using AlphaFold. We therefore chose to show only experimental results in the main text figures. Through phage plaque, bacterial growth, and colony formation assays, the authors show that SSBs from phages T3, T4, T5, and T7 can all activate DARNA-mediated defense or toxicity. While the data is very convincing, not all mentioned phage SSBs are represented in each assay. The preprint as a whole would benefit from including all SSBs in each experiment, and either including the data in the main figures or moving the data to the supplement. It will be interesting to know if each SSB functions similarly in each experiment. Response. We agree that comparing all phage SSBs across the different assays would be most informative. However, some of these proteins are highly similar (e.g., T3 and T7 SSBs), and we therefore considered testing all of them in every assay redundant. In our initial experiments, we tested three distinct phage SSBs (T4, T5, and T7) and confirmed that all three can activate DARNA-mediated toxicity (Figure 1C). For subsequent experiments, we chose to focus on T7 SSB for several reasons: it is a well-characterized protein, the effects of mutations such as Y158C and Δ232F on its function have been described in the literature, and the escaper mutant identified in our study harbored a singl
Author: Giedrius Sasnauskas
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7234420018
